The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
 
Rohit K. Jain
Honoraria - Curio Science; DAVA Oncology; NCCN/Pfizer; OncLive/MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Gilead Sciences; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Gilead Sciences; Seagen; Seattle Genetics/Astellas
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
 
Yuanquan Yang
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - The whiteoak group
Research Funding - Amgen (Inst); Incyte (Inst); Novartis (Inst)
 
Juskaran Chadha
No Relationships to Disclose
 
Monica Sheila Chatwal
Speakers' Bureau - Merck
 
Julie Ann Kish
No Relationships to Disclose
 
Sarah Raymond
No Relationships to Disclose
 
Jennifer Rembisz
No Relationships to Disclose
 
Ghazal Jameel
No Relationships to Disclose
 
Arfa Mustasam
No Relationships to Disclose
 
Trey Poehlman
No Relationships to Disclose
 
Wenyi Fan
No Relationships to Disclose
 
Youngchul Kim
No Relationships to Disclose
 
Jasreman Dhillon
No Relationships to Disclose
 
Carlos A. Alemany
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Dendreon; EMD Serono; Pfizer; Sanofi; Sanofi/Aventis; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Dendreon; EMD Serono; Pfizer
Speakers' Bureau - AstraZeneca; Dendreon; Sanofi; Seagen
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics